Soluble expression and purification of hepatitis B core antigen (HBcAg) subgenotype B3 in Escherichia coli using thioredoxin fusion tag

Potential of Nanoparticles Chitosan for Delivery pcDNA3.1-SB3-HBcAg

“…In this study, a synthetic DNA vaccine was designed based on the nucleotide base sequence of hepatitis B gene core antigen B3 subgenotype HBcAg [2]. The consensus sequence was optimized using codon optimization with target host Bos taurus using the services of Gene Universal Inc. Several motif sequences that potentially produce lower expression such as Chi site (GCTGGTGG), ter site core (GTTGTAAC), polyA sites (AATAAA or ATTAAA), consensus eukaryotic promoter core (TATA), immunosuppressive telomeric motif (TTAGGG), DNA uptake sequences (GCCGTCTGAA, AAGTGCGGT or ACAAGCGGTC), consensus splice donor (AGGT), consensus splice acceptor (CAGG), polyA binding proteins consensus (AAAAA), polyT binding proteins consensus (TTTTT) and DnaA binding site (TTATCCACA) were substituted using codon optimization process [7].…”

“…Codon optimization is carried out using the services of Gene Universal Corp. The optimized base sequence of the SB3HBcAg gene is derived from the nucleotide base sequence of the Hepatitis B core antigen B3 HBcAg subgenotype [2]. The results of the optimization of the codon of the SB3-HBcAg gene are shown in Figure 1A.…”

“…It is estimated that as many as 2 billion people have been infected, 350 million of which have developed chronic infections causing 600,000 deaths each year. Indonesia is one of the countries with the highest prevalence of HBsAg, ranging from 2.5% to 10% [1], with the highest rates reported in North Sulawesi at 33.0%, Papua at 12.8% and the lowest in Jakarta 4.0% [2].…”

“…One type of vaccine which is a new breakthrough in vaccine technology is DNA vaccine. DNA vaccines are made by inserting DNA or genes encoding immunogenic proteins into eukaryotic expression vectors [2]. One of the structural genes of HBV used as a source of DNA vaccines is the HBcAg gene (HBV/B subgenotype B3).…”

“…HBcAg was chosen as a vaccine candidate because it is more specific for cytotoxic T lymphocytes (CTL) in the liver. CTL secretes the cytokines TNF-and interferon, both of which will affect infected hepatocytes, so that HBV replication in these cells can be inhibited [2].…”